Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.

Acta neuropathologica·2026
Same author

Characterizing the MRI signature of hippocampal sclerosis of aging.

Alzheimer's research & therapy·2026
Same author

Mucoadhesive amphiphilic polymers for buccal drug delivery: overcoming solubility and permeation barriers.

Journal of biomaterials science. Polymer edition·2026
Same author

The Biobank Rare Variant consortium powers the discovery of rare genetic associations through global collaboration.

medRxiv : the preprint server for health sciences·2026
Same author

Clinicoanatomic localization of iron-rich gliosis in aphasic presentations of globular glial tauopathy.

Brain communications·2026
Same author

Multifunctional saponin-based nanocarriers for targeting oral delivery of hydrophobic drugs: linking molecular architecture with bioavailability enhancement.

International journal of pharmaceutics·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Katheryn A Q Cousins1, Rory Boyle2, Colleen Morse3

  • 1Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

This study shows that the plasma p-tau217/Aβ42 ratio is a promising Alzheimer's disease biomarker in diverse populations. It accurately classifies disease status and is less affected by comorbidities than other biomarkers.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neurology
  • Biomarkers
  • Alzheimer's Disease Research

Background:

  • Plasma biomarkers for Alzheimer's disease (AD) are crucial but often limited by research settings.
  • This study evaluated plasma biomarkers in a real-world, diverse dataset with multimorbidities.

Purpose of the Study:

  • To assess the generalizability of plasma biomarkers for Alzheimer's disease (AD) pathology.
  • To evaluate the impact of comorbidities on plasma biomarker levels in a diverse population.

Main Methods:

  • Utilized electronic health records from 683 participants (298 Black/African American, 385 White).
  • Classified participants into AD dementia (ADD), mild cognitive impairment (MCI), cognitive impairment (CI), and cognitively normal groups using ICD codes.
  • Analyzed plasma biomarkers including phosphorylated tau 217 (p-tau217) and β-amyloid 1-42/1-40 (Aβ42/Aβ40), assessing relationships with comorbidities, demographics, and APOE ε4 status.

Main Results:

  • The p-tau217/Aβ42 ratio was elevated in MCI and ADD and correlated with age, female sex, APOE ε4, and creatinine.
  • Plasma p-tau217 levels showed similar associations, while Aβ42/Aβ40 decreased with age, higher ALT, LDL-cholesterol, and diabetes.
  • Biomarker positivity did not differ significantly by race. The p-tau217/Aβ42 ratio had the lowest rate of undetermined cases (15%).

Conclusions:

  • Plasma biomarkers, particularly the p-tau217/Aβ42 ratio, show potential for real-world AD diagnosis.
  • Comorbidities like diabetes and impaired kidney function affect plasma biomarker levels.
  • The p-tau217/Aβ42 ratio may offer a more robust measure by accounting for some comorbidity effects, though creatinine remains a confounder.